ARTICLE | Company News
AgonOx, AstraZeneca deal
November 7, 2011 8:00 AM UTC
AgonOx partnered with AstraZeneca's MedImmune LLC subsidiary to develop agonists using AgonOx's OX40 ligand ( OX40L; CD134L) technology to treat cancer. MedImmune will lead further preclinical and clinical studies. Details were not disclosed. ...